X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (19) 19
female (11) 11
male (11) 11
melanoma (10) 10
index medicus (9) 9
middle aged (9) 9
ipilimumab (8) 8
oncology (8) 8
antineoplastic agents - therapeutic use (7) 7
melanoma - drug therapy (7) 7
adult (6) 6
antibodies, monoclonal - therapeutic use (6) 6
neoplasm staging (6) 6
treatment outcome (6) 6
aged (5) 5
care and treatment (5) 5
clinical trials (5) 5
melanoma - pathology (5) 5
metastasis (5) 5
patients (5) 5
quality of life (5) 5
survival analysis (5) 5
advanced melanoma (4) 4
analysis (4) 4
cancer (4) 4
economics, pharmaceutical (4) 4
medical care, cost of (4) 4
penicillanic acid - administration & dosage (4) 4
penicillanic acid - analogs & derivatives (4) 4
piperacillin - administration & dosage (4) 4
research (4) 4
retrospective studies (4) 4
skin cancer (4) 4
studies (4) 4
adolescent (3) 3
anti-bacterial agents - pharmacology (3) 3
antibiotics (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
cancer therapies (3) 3
cost analysis (3) 3
costs (3) 3
disease-free survival (3) 3
double-blind method (3) 3
drug dosages (3) 3
health care sciences & services (3) 3
health economics (3) 3
hospital costs (3) 3
infections (3) 3
length of stay (3) 3
melanoma - mortality (3) 3
pharmacology & pharmacy (3) 3
piperacillin-tazobactam (3) 3
skin neoplasms - drug therapy (3) 3
survival (3) 3
thienamycins - administration & dosage (3) 3
adjuvants, immunologic - therapeutic use (2) 2
adverse events (2) 2
aged, 80 and over (2) 2
anti-bacterial agents - administration & dosage (2) 2
anti-bacterial agents - pharmacokinetics (2) 2
anti-bacterial agents - therapeutic use (2) 2
antibodies, monoclonal - administration & dosage (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic agents - economics (2) 2
article (2) 2
case-control studies (2) 2
cefepime (2) 2
clinical trials, phase iii as topic (2) 2
comparative analysis (2) 2
confidence intervals (2) 2
connecticut (2) 2
cooperative-oncology-group (2) 2
cost control (2) 2
cost-benefit analysis - economics (2) 2
cutaneous melanoma (2) 2
development and progression (2) 2
drug therapy (2) 2
economic aspects (2) 2
economics (2) 2
efficacy (2) 2
end-points (2) 2
escherichia coli - drug effects (2) 2
escherichia coli - enzymology (2) 2
escherichia coli infections - drug therapy (2) 2
escherichia coli infections - microbiology (2) 2
fda approval (2) 2
health administration (2) 2
health aspects (2) 2
health policy & services (2) 2
health-related quality of life (2) 2
high-dose interleukin-2 (2) 2
immune checkpoint (2) 2
immunotherapy (2) 2
infectious diseases (2) 2
infusions, intravenous - economics (2) 2
interferon (2) 2
ipilimumab - therapeutic use (2) 2
klebsiella - classification (2) 2
klebsiella - drug effects (2) 2
klebsiella - enzymology (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Experimental hematology & oncology, ISSN 2162-3619, 2019, Volume 8, Issue 1, pp. 14 - 10
Monoclonal antibodies targeting the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) (e.g., ipilimumab [IPI]) and the programmed cell death-1 (PD1) receptor... 
Usage | Care and treatment | Analysis | Ipilimumab | Melanoma | Development and progression | Comparative analysis | Medical care, Cost of | Systematic review | Metastasis | Cost analysis | Patients | Cancer therapies | Drug dosages | Skin cancer | Healthcare cost comparison | Advanced melanoma | Nivolumab | CheckMate 067
Journal Article
Cancer Medicine, ISSN 2045-7634, 07/2016, Volume 5, Issue 7, pp. 1436 - 1443
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. 9531 - 9531
Journal Article
European Journal of Cancer, ISSN 0959-8049, 09/2017, Volume 82, p. 80
Background: Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint... 
Therapy | PD-1 protein | Melanoma | Clinical trials | Cytotoxicity | Lymphocytes T | Patients | Subgroups | Quality of life | Side effects | CTLA-4 protein | Immune checkpoint | Lymphocytes | Monoclonal antibodies | Drug therapy | Apoptosis
Journal Article
Health Outcomes Research in Medicine, ISSN 1877-1319, 2012, Volume 3, Issue 1, pp. e25 - e36
Abstract Objective Overall survival is a commonly reported end point in clinical trial publications and a key determinant of therapies’ cost-effectiveness.... 
Internal Medicine | Survival analysis | Oncology | Overall survival | Modeling
Journal Article
The Oncologist, ISSN 1083-7159, 11/2012, Volume 17, Issue 11, pp. 1376 - 1385
摘要 目的: 比较易普利单抗3 mg/kg与替代全身疗法治疗经治不可切除III或IV期黑色素瘤患者的总生存期(OS)。 方法: 通过系统文献检索查找相关随机临床试验。从这些试验中,将每种药物干预的Kaplan‐Meier生存曲线数字化并通过Bayesian网络荟萃分析(NMA)结合用于比较不同的药物类别。 结果:... 
Network meta analysis | Survival | Ipilimumab | Melanoma | COLONY-STIMULATING FACTOR | HYDROXYUREA NSC-32065 | METASTATIC MALIGNANT-MELANOMA | INTERFERON ALPHA-2A | ISPOR TASK-FORCE | ONCOLOGY | RANDOMIZED PHASE-II | ACTIVATED KILLER-CELLS | DOUBLE-BLIND | HIGH-DOSE INTERLEUKIN-2 | COOPERATIVE-ONCOLOGY-GROUP | Skin Neoplasms - drug therapy | Humans | Kaplan-Meier Estimate | Antibodies, Monoclonal - therapeutic use | Treatment Outcome | Antineoplastic Agents - therapeutic use | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Skin Neoplasms - mortality | Immunotherapy | Melanoma - drug therapy | Survival Analysis | Neoplasm Staging | Melanoma - mortality | Academia-Pharma Intersect
Journal Article